Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Pipeline Monitor
Novartis files biosim for Enbrel
Novartis' generic arm, Sandoz has had its filing for US approval of a biosimilar version of Pfizer's Enbrel accepted by the FDA.
Working Life
What makes a good sales rep
Award-winning sales representatives share their views on what it takes to sell medicines in today's fast changing environment.
Approvals Action
UCB's number two PBS drug under threat
Apotex has registered the first competition to UCB's second-biggest earning PBS drug while Boehringer puts up a new COPD brand.
Special Report
Why MA Code complaints are waning
Complaints under the Medicines Australia Code appear to be in decline. Some say it's better compliance and improved inter-company dialogue but others say spikes can still be expected when rules change.